keyword
https://read.qxmd.com/read/38535330/elucidation-and-regulation-of-tyrosine-kinase-inhibitor-resistance-in-renal-cell-carcinoma-cells-from-the-perspective-of-glutamine-metabolism
#21
JOURNAL ARTICLE
Kento Morozumi, Yoshihide Kawasaki, Tomonori Sato, Masamitsu Maekawa, Shinya Takasaki, Shuichi Shimada, Takanari Sakai, Shinichi Yamashita, Nariyasu Mano, Akihiro Ito
Tyrosine kinase inhibitors (TKIs) play a crucial role in the treatment of advanced renal cell carcinoma (RCC). However, there is a lack of useful biomarkers for assessing treatment efficacy. Through urinary metabolite analysis, we identified the metabolites and pathways involved in TKI resistance and elucidated the mechanism of TKI resistance. To verify the involvement of the identified metabolites obtained from urine metabolite analysis, we established sunitinib-resistant RCC cells and elucidated the antitumor effects of controlling the identified metabolic pathways in sunitinib-resistant RCC cells...
March 19, 2024: Metabolites
https://read.qxmd.com/read/38534999/a-comparison-of-68-ga-psma-pet-ct-based-split-renal-function-with-99m-tc-mag3-renography-in-patients-with-metastatic-castration-resistant-prostate-carcinoma-treated-with-177-lu-psma
#22
JOURNAL ARTICLE
Lerato Gabela, Thokozani Mkhize, Bawinile Hadebe, Lerwine Harry, Thembelihle Nxasana, Nontobeko Ndlovu, Venesen Pillay, Sphelele Masikane, Maryam Patel, Nozipho Elizabeth Nyakale, Mariza Vorster
BACKGROUND: Physiological PSMA expression in the cells of the proximal renal tubules and consecutive radiopharmaceutical binding and retention could potentially lead to radioligand-therapy-induced nephrotoxicity. Thus, patients with metastatic castration-resistant prostate cancer undergo 99m Tc-Mercaptoacetyltriglycine (MAG3) renal scintigraphy to assess kidney function and to exclude renal obstruction as part of their workup for PSMA-targeted radioligand therapy (RLT). 99m Tc-MAG-3 renal scintigraphy often requires an additional visit to the nuclear medicine department and patients spend 30-90 min in the department, which is inconvenient and takes up camera time...
March 8, 2024: Diagnostics
https://read.qxmd.com/read/38534739/ferroptosis-related-lncrna-to-predict-the-clinical-outcomes-and-molecular-characteristics-of-kidney-renal-papillary-cell-carcinoma
#23
JOURNAL ARTICLE
Yubo Gong, Chenchen Zhang, Hao Li, Xiaojie Yu, Yuejia Li, Zhiguo Liu, Ruyi He
Kidney renal papillary cell carcinoma (KIRP) is a highly heterogeneous type of kidney cancer, resulting in limited effective prognostic targets for KIRP patients. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in the regulation of ferroptosis and iron metabolism, making them potential targets for the treatment and prognosis of KIRP. In this study, we constructed a ferroptosis-related lncRNA risk score model (FRM) based on the TCGA-KIRP dataset, which represents a novel subtype of KIRP not previously reported...
February 29, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38534315/cisplatin-and-starvation-differently-sensitize-autophagy-in-renal-carcinoma-a-potential-therapeutic-pathway-to-target-variegated-drugs-resistant-cancerous-cells
#24
JOURNAL ARTICLE
Ankita Dutta, Subarna Thakur, Debasish Kumar Dey, Anoop Kumar
Cisplatin, a powerful chemotherapy medication, has long been a cornerstone in the fight against cancer due to chemotherapeutic failure. The mechanism of cisplatin resistance/failure is a multifaceted and complex issue that consists mainly of apoptosis inhibition through autophagy sensitization. Currently, researchers are exploring ways to regulate autophagy in order to tip the balance in favor of effective chemotherapy. Based on this notion, the current study primarily identifies the differentially expressed genes (DEGs) in cisplatin-treated autophagic ACHN cells through the Illumina Hi-seq platform...
March 7, 2024: Cells
https://read.qxmd.com/read/38531662/impact-of-immunotherapy-time-of-day-infusion-on-survival-and-immunologic-correlates-in-patients-with-metastatic-renal-cell-carcinoma-a-multicenter-cohort-analysis
#25
MULTICENTER STUDY
Jimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Viraj A Master, Mehmet A Bilen, Mohammad K Khan, Michael C Lowe, Haydn Kissick, Zachary S Buchwald, David C Qian
BACKGROUND: Recent studies have demonstrated that earlier time-of-day infusion of immune checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma and non-small cell lung cancer. These data are in line with growing preclinical evidence that the adaptive immune response may be more effectively stimulated earlier in the day. We sought to determine the impact of time-of-day ICI infusions on outcomes among patients with metastatic renal cell carcinoma (mRCC)...
March 26, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38531002/randomized-double-blind-phase-iii-study-of-pazopanib-versus-placebo-in-patients-with-metastatic-renal-cell-carcinoma-who-have-no-evidence-of-disease-after-metastasectomy-ecog-acrin-e2810
#26
JOURNAL ARTICLE
Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins, Jill Kolesar, Neeraj Agarwal, Rahul A Parikh, Daniel A Vaena, Christopher W Ryan, Mehmood Hashmi, Brian A Costello, David Cella, Janice P Dutcher, Robert S DiPaola, Naomi B Haas, Lynne I Wagner, Michael A Carducci
PURPOSE: Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy...
March 26, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38530480/cancer-specific-mortality-in-non-metastatic-t1a-renal-cell-carcinoma-treated-with-radiotherapy-versus-partial-nephrectomy
#27
JOURNAL ARTICLE
Mario de Angelis, Simone Morra, Lukas Scheipner, Carolin Siech, Letizia Maria Ippolita Jannello, Andrea Baudo, Jordan A Goyal, Zhe Tian, Nicola Longo, Sascha Ahyai, Ottavio de Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
PURPOSE: Radiotherapy (RT) represents a treatment option for small renal masses with proven feasibility and tolerability. However, it has never been directly compared to partial nephrectomy (PN) with cancer-specific mortality (CSM) as an endpoint. METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified T1aN0M0 renal cell carcinoma (RCC) patients treated with RT or PN. We relied on 1:1 propensity score matching (PSM) for age, tumor size and histology...
March 26, 2024: World Journal of Urology
https://read.qxmd.com/read/38527980/immunoexpression-of-ki67-p16-and-beta-catenin-in-precursor-lesions-of-cutaneous-squamous-cell-carcinoma
#28
JOURNAL ARTICLE
Alina Maria Vîlcea, Loredana Elena Stoica, Bianca Cătălina Andreiana, Cecil Sorin Mirea, Tiberiu Ştefăniţă Ţenea Cojan, Ioana Cristina Vîlcea, Claudiu Mărgăritescu
Cutaneous squamous cell carcinoma (CSCC) is the second most common type of skin cancer, after basal cell carcinoma, representing about 10-20% of all malignant skin tumors. The mortality rates of CSCC approach those of renal and oropharyngeal carcinomas, as well as melanoma, with the increasing of the risk once metastases and perineural invasion occur. Both actinic keratosis (AK) and Bowen's disease (BD) are direct precursors with the potential for progression to CSCC. In this study, we analyzed the expression of Ki67, P16 and Beta-catenin in the precursor lesions of CSCC in relation to histological prognostic parameters, respectively between them, with the aim of identifying possible correlations with a role in prognosis...
2024: Romanian Journal of Morphology and Embryology
https://read.qxmd.com/read/38527174/role-of-interleukin-1-receptor-2-in-kidney-disease
#29
JOURNAL ARTICLE
Huiyue Hu, Aihua Wu, Xiaodie Mu, Hua Zhou
The interleukin 1 (IL-1) family plays a significant role in the innate immune response. IL-1 receptor 2 (IL-1R2) is the decoy receptor of IL-1. It is a negative regulator that can be subdivided into membrane-bound and soluble types. IL-1R2 plays a role in the IL-1 family mainly through the following mechanisms: formation of inactive signaling complexes upon binding to the receptor auxiliary protein and inhibition of ligand IL-1 maturation. This review covers the roles of IL-1R2 in kidney disorders. Chronic kidney disease, acute kidney injury, lupus nephritis, IgA nephropathy, renal clear cell carcinoma, rhabdoid tumor of kidney, kidney transplantation, and kidney infection were all shown to have abnormal IL-1R2 expression...
March 22, 2024: Journal of Interferon & Cytokine Research
https://read.qxmd.com/read/38525552/cystic-features-in-renal-epithelial-neoplasms-and-their-increasing-clinical-and-pathologic-significance
#30
JOURNAL ARTICLE
Maria Tretiakova, Jung Woo Kwon, Gladell P Paner
Most cystic renal tumors after resection (Boniak IIF to IV cysts) have an indolent course despite the significantly higher proportion of malignant [ie, renal cell carcinoma (RCC)] diagnosis. Most cystic renal tumors have clear cell histology that include cystic clear cell RCC and multilocular cystic renal neoplasm of low malignant potential (MCNLMP). There is growing evidence to suggest that MCNLMP, cystic clear cell RCC, and noncystic clear cell RCC form a cystic-to-solid biological spectrum with MCNLMP representing the most indolent form and with cystic clear cell RCC behaving better than noncystic (solid) clear cell RCC...
March 25, 2024: Advances in Anatomic Pathology
https://read.qxmd.com/read/38525093/nivolumab-safety-in-renal-cell-carcinoma-a-case-report
#31
James Debono, Dustin Balzan, John Joseph Borg, Stephen Falzon, Dania Al-Haddad, Benjamin Micallef, Janet Sultana
Nivolumab is used to treat several different types of cancers. Although it is generally considered to be effective and well-tolerated, it has been associated with adverse effects requiring discontinuation of treatment, like many other drugs used for cancer. A 70-year-old male was switched from sunitinib to nivolumab for renal cell carcinoma. The patient developed persistent hypothyroidism, onycholysis, and pneumonitis at nivolumab cycle 6, 10, and 11, respectively. Using the Naranjo causality method, the likelihood of causality was deemed "probable" for pneumonitis and hypothyroidism and "possible" for onycholysis...
April 2024: Journal of Pharmacy Technology: JPT: Official Publication of the Association of Pharmacy Technicians
https://read.qxmd.com/read/38524877/understanding-sorafenib-induced-cardiovascular-toxicity-mechanisms-and-treatment-implications
#32
REVIEW
Jue Li, Lusha Zhang, Teng Ge, Jiping Liu, Chuan Wang, Qi Yu
Tyrosine kinase inhibitors (TKIs) have been recognized as crucial agents for treating various tumors, and one of their key targets is the intracellular site of the vascular endothelial growth factor receptor (VEGFR). While TKIs have demonstrated their effectiveness in solid tumor patients and increased life expectancy, they can also lead to adverse cardiovascular effects including hypertension, thromboembolism, cardiac ischemia, and left ventricular dysfunction. Among the TKIs, sorafenib was the first approved agent and it exerts anti-tumor effects on hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) by inhibiting angiogenesis and tumor cell proliferation through targeting VEGFR and RAF...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38524649/intratumoral-metastasis-of-sigmoid-colon-cancer-to-chromophobe-renal-cell-carcinoma-a-case-report
#33
JOURNAL ARTICLE
Suzuna Sakai, Kojiro Ohba, Kazunari Migita, Ichiro Sekine, Yasuto Yamazaki
We herein report an extremely rare case of intratumoral metastasis of colon cancer to chromophobe renal cell carcinoma. A 71-year-old woman was diagnosed with lung metastasis of sigmoid colon cancer and underwent sigmoid colon resection with D3 lymph node dissection. Preoperative contrast-enhanced computed tomography (CT) revealed a left renal tumor; however, colon resection was prioritized, and the renal tumor was placed under observation. Two years later, CT revealed enlargement of the left renal tumor, and laparoscopic partial left nephrectomy was performed 1 month later...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524647/a-case-of-postoperative-pancreatitis-in-patients-with-renal-cell-carcinoma-with-an-inferior-vena-cava-tumor-thrombus-treated-by-presurgical-lenvatinib-plus-pembrolizumab
#34
JOURNAL ARTICLE
Masahiro Kurokawa, Daiki Ikarashi, Renpei Kato, Mitsugu Kanehira, Takashi Fukagai, Wataru Obara
Pancreatic injury is a rare, but noted complication of nephrectomy. We report a case involving a 56-year-old man who presented with cT3bN0M0 left locally advanced renal cell carcinoma with an inferior vena cava thrombus. Nephrectomy with thrombectomy was performed given the remarkable shrinkage of the primary tumor and thrombus following lenvatinib plus pembrolizumab administration. The patient developed postoperative pancreatitis associated with unrecognized minor pancreatic injury, which was treated conservatively...
April 2024: International cancer conference journal
https://read.qxmd.com/read/38524578/novel-insights-into-post-marketing-adverse-events-associated-with-lenvatinib-a-comprehensive-analysis-utilizing-the-faers-database
#35
JOURNAL ARTICLE
Zhe Yu, Jing Luo, Hongshan Wei
PURPOSE: The primary aim of this study was to closely monitor and identify adverse events (AEs) linked to lenvatinib, a pharmacotherapeutic agent employed for the management of renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. The ultimate goal was to optimize patient safety and provide evidence-based guidance for the appropriate utilization of this medication. METHODS: A comprehensive collection and analysis of reports from the FDA Adverse Event Reporting System (FAERS) database was conducted, encompassing the period from the first quarter of 2015 to the first quarter of 2023...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38523833/a-curious-case-concurrent-collecting-duct-renal-cell-carcinoma-and-upper-tract-urothelial-carcinoma
#36
Adib Rahman, Daniel Matheson, Joanna Perry-Keene, Devang Desai
A 71-year-old male presented to Urology with three weeks of overt haematuria and increasing lethargy. Contrast-enhanced CT scans revealed an 8 × 6cm partially exophytic lesion in the left kidney's upper pole, extending beyond the capsule and invading the superior cortical vein, accompanied by abnormal retrocrural lymph nodes. Signs of paraneoplastic syndrome prompted a left radical nephrectomy for symptom relief. Histological analysis identified high-grade collecting duct renal carcinoma and invasive urothelial cell carcinoma...
May 2024: Urology Case Reports
https://read.qxmd.com/read/38523726/breast-metastasis-an-unusual-cause-of-malignant-breast-lesion
#37
JOURNAL ARTICLE
Dunkan Petersbourg
Teaching point: Although rare, an intra-mammary metastasis from extramammary cancer should be considered in a patient with an oncological history.
2024: Journal of the Belgian Society of Radiology
https://read.qxmd.com/read/38523633/arachidonic-acid-metabolism-as-a-therapeutic-target-in-aki-to-ckd-transition
#38
REVIEW
Xiao-Jun Li, Ping Suo, Yan-Ni Wang, Liang Zou, Xiao-Li Nie, Ying-Yong Zhao, Hua Miao
Arachidonic acid (AA) is a main component of cell membrane lipids. AA is mainly metabolized by three enzymes: cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450). Esterified AA is hydrolysed by phospholipase A2 into a free form that is further metabolized by COX, LOX and CYP450 to a wide range of bioactive mediators, including prostaglandins, lipoxins, thromboxanes, leukotrienes, hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids. Increased mitochondrial oxidative stress is considered to be a central mechanism in the pathophysiology of the kidney...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38521648/association-of-cabozantinib-dose-reductions-for-toxicity-with-clinical-effectiveness-in-metastatic-renal-cell-carcinoma-mrcc-results-from-the-canadian-kidney-cancer-information-system-ckcis
#39
JOURNAL ARTICLE
Jeffrey Graham, Sunita Ghosh, Rodney H Breau, Lori Wood, Simon Tanguay, Dominick Bosse, Aly-Khan Lalani, Bimal Bhindi, Daniel Heng, Antonio Finelli, Nazanin Fallah-Rad, Vincent Castonguay, Naveen S Basappa, Denis Soulières, Frédéric Pouliot, Christian Kollmannsberger, Georg A Bjarnason
BACKGROUND: Cabozantinib, an oral multi-targeted tyrosine kinase inhibitor (TKI), has demonstrated efficacy in metastatic renal cell carcinoma (mRCC). The association between toxicity and therapeutic effectiveness has been established with other TKIs. We investigated whether cabozantinib dose reductions, a surrogate for toxicity and adequate drug exposure, were associated with improved clinical outcomes in mRCC. METHODS: Employing the CKCis database, we analyzed patients treated with cabozantinib in the second line or later between 2011 to 2021...
February 23, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38521617/avelumab-plus-intermittent-axitinib-in-previously-untreated-patients-with-metastatic-renal-cell-carcinoma-the-tide-a-phase-2-study
#40
JOURNAL ARTICLE
Roberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, Paolo Andrea Zucali, Emanuela Fantinel, Davide Bimbatti, Elena Verzoni, Caterina Accettura, Lucia Bonomi, Consuelo Buttigliero, Giuseppe Fornarini, Stefania Pipitone, Francesco Atzori, Cristina Masini, Francesco Massari, Francesca Primi, Alessandro Strusi, Giulia Claire Giudice, Matteo Perrino, Marco Maruzzo, Michele Milella, Diana Giannarelli, Matteo Brunelli, Giuseppe Procopio, Giampaolo Tortora
BACKGROUND: Combinations of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitor (ICI) against PD1/PD-L1 are the standard first-line therapy for patients with metastatic renal cell carcinoma (mRCC), irrespective of the prognostic class. OBJECTIVE: To investigate the feasibility and safety of withdrawing VEGFR-TKI but continuing anti-PD1/PD-L1 in patients who achieve a response to their combination...
March 22, 2024: European Urology
keyword
keyword
116101
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.